{'52WeekChange': -0.027397215,
 'SandP52WeekChange': None,
 'address1': '47 Thorndike Street',
 'address2': 'Suite B1-1',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.18,
 'askSize': 800,
 'averageDailyVolume10Day': 2037725,
 'averageVolume': 800495,
 'averageVolume10days': 2037725,
 'beta': 1.951644,
 'beta3Year': None,
 'bid': 2.15,
 'bidSize': 3000,
 'bookValue': 0.502,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 2.175,
 'dayLow': 2.02,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.72,
 'enterpriseToRevenue': 141.474,
 'enterpriseValue': 53052888,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 2.1381428,
 'fiftyTwoWeekHigh': 3.18,
 'fiftyTwoWeekLow': 0.573,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 21258094,
 'forwardEps': -0.69,
 'forwardPE': -3.1449277,
 'fromCurrency': None,
 'fullTimeEmployees': 24,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.20064,
 'heldPercentInstitutions': 0.48183,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/leaptx.com',
 'longBusinessSummary': 'Leap Therapeutics, Inc., a biopharmaceutical company, '
                        'acquires and develops therapies for the treatment of '
                        'cancer. Its clinical stage programs include DKN-01, a '
                        'monoclonal antibody that inhibits Dickkopf-related '
                        'protein 1 that is in clinical trials for treating '
                        'esophagogastric cancer, hepatobiliary cancer, '
                        'gynecologic cancers, and prostate cancer. The '
                        "company's clinical stage programs also include "
                        'TRX518, a monoclonal antibody, which is in clinical '
                        'trial targeting the glucocorticoid-induced tumor '
                        'necrosis factor-related receptor in patients with '
                        'solid tumors. The company was formerly known as '
                        'HealthCare Pharmaceuticals, Inc. and changed its name '
                        'to Leap Therapeutics, Inc. in November 2015. Leap '
                        'Therapeutics, Inc. was founded in 2011 and is based '
                        'in Cambridge, Massachusetts.',
 'longName': 'Leap Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 128951168,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_118044172',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -41602000,
 'nextFiscalYearEnd': 1640908800,
 'open': 2.16,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.88,
 'phone': '617-714-0360',
 'previousClose': 2.13,
 'priceHint': 4,
 'priceToBook': 4.3227096,
 'priceToSalesTrailing12Months': 343.86978,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 2.175,
 'regularMarketDayLow': 2.02,
 'regularMarketOpen': 2.16,
 'regularMarketPreviousClose': 2.13,
 'regularMarketPrice': 2.16,
 'regularMarketVolume': 920231,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 59424500,
 'sharesPercentSharesOut': 0.0212,
 'sharesShort': 1190335,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1363565,
 'shortName': 'Leap Therapeutics, Inc.',
 'shortPercentOfFloat': 0.0318,
 'shortRatio': 1.22,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'LPTX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.62,
 'twoHundredDayAverage': 2.0444245,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '9c2a03e8-27dc-34be-8377-0c5e52ed941b',
 'volume': 920231,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.leaptx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02141'}